Price T Rowe Associates Inc Ocugen, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Ocugen, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 113,072 shares of OCGN stock, worth $76,888. This represents 0.0% of its overall portfolio holdings.
Number of Shares
113,072
Previous 235,860
52.06%
Holding current value
$76,888
Previous $235,000
61.28%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding OCGN
# of Institutions
123Shares Held
68.6MCall Options Held
478KPut Options Held
253K-
Black Rock Inc. New York, NY17.9MShares$12.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.6MShares$11.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.59MShares$4.48 Million0.0% of portfolio
-
State Street Corp Boston, MA5.87MShares$3.99 Million0.0% of portfolio
-
Gmt Capital Corp Atlanta, GA2.45MShares$1.67 Million0.1% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $147M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...